6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

P. Thuss-Patience, Peter Reichardt(Helios Hospital Berlin-Buch), Bernhard Gebauer(Charité - Universitätsmedizin Berlin), Dmitry Bichev(Charité - Universitätsmedizin Berlin), Guido Schumacher(Charité - Universitätsmedizin Berlin), Axel Hinke, Albrecht Kretzschmar(Roche (Switzerland)), B. Lebedinzew(Helios Hospital Bad Saarow), Timo M. Deist(Helios Hospital Bad Saarow)

European Journal of Cancer Supplements

September 1, 2009

10.1016/s1359-6349(09)71226-1

Cited by 9

Related Papers

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

|European Journal of Cancer|2019|724